You are currently viewing a new version of our website. To view the old version click .

Druggability of Proteins/Enzymes

This special issue belongs to the section “Drug Discovery, Development and Delivery“.

Special Issue Information

Dear Colleagues,

This Special Issue will cover all aspects of research works on druggable proteins and enzymes.

The human genome encodes approximately 20,000 proteins, a handful of which are suitable for drug–protein interactions. Within this group, even fewer are effectively targeted by drugs. This subgroup is defined here as the druggable proteins/enzymes with a specific affinity to bind small molecule(s) or antibodies mediating a signal transduction network involved in disease control.

Suitable manuscripts include, but are not limited to, research and review manuscripts that address enzyme and protein activities targeted by drugs converting signal transduction from the site of interaction into specific responses inside the cell resulting, for example, in gene expression, cell division, and/or cell death.

Research works of antibody-based drugs that cannot pass the plasma membrane are also welcome as they are mostly directed against protein targets on the cell surface (receptors) affecting their activities.

Additional druggable proteins that are of interest include, but are not limited to, all works on transporters, G-protein coupled receptors, CD markers, nuclear receptors, voltage-gated ion channels, etc.

Dr. Ruth Vinall
Dr. Simeon Kotchoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug
  • antibodies
  • enzymes
  • target
  • druggable proteomics
  • druggable enzymolomics
  • disease
  • signal transduction
  • transporters
  • channel proteins
  • cell division
  • cell death
  • pathway inhibition
  • gene expression
  • computational biology
  • vaccine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Biomedicines - ISSN 2227-9059